AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03460184 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: G.A Group A:
Description: G.A will be conducted After pre-oxygenation for 3-5 minutes. thiopental (5 mg/kg) will be administered I.V, followed by succinylcholine 1.5 mg/kg. After tracheal intubation, the patients will be ventilated with 100% oxygen. isoflurane 0.8% will be added, to maintain the anesthesia. Further neuromuscular block will be maintained by using atracurium . After delivery of the fetus, fentanyl IV will be given 1ug/kg as analgesia and 20 IU oxytocin will be given by I.V infusion .Reverse neuromuscular blockade as necessary at completion of surgery. Extubate when the patient is awake~In the sitting position and after complete asepsis , 2-3 ml of Lidocaine will be injected subcutaneously, spinal anesthesia will be performed at interspace L3-4 or L4-5, midline approaches using 22 guage Quinke needle . 2.5 ml of hyperbaric bupivacaine 0.5% in addition to 25 μg fentanyl will be injected into the subarachnoid space after successful dural puncture and confirmation by barbotage.
Study NCT02215070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.
Study NCT02049489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICT-121 DC vaccine
Description: autologous dendritic cells pulsed with peptide antigens
Study NCT00802217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Civamide
Description: 5 mg liquid filled softgel capsules
Study NCT00802217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Civamide
Description: 5 mg x 2 liquid softgel capsules
Study NCT01707004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT01707004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT01707004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV
Study NCT01707004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01707004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given PO or IV
Study NCT01707004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO
Study NCT01707004 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT01707004 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo total-body irradiation
Study NCT01707004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo allogeneic bone marrow transplantation
Study NCT01707004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03041259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rejuveinix Low Dose
Description: A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
Study NCT03041259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rejuveinix High Dose
Description: A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
Study NCT02042976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy
Study NCT02042976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Study NCT02042976 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Study NCT03684200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Copenhagen adductor exercise
Description: The active player is supported on one forearm on the floor and the upper arm is resting along their side. The supporting partner places their hands at the ankle and the knee of the upper leg. The active partner raises their body from the floor and adducts both legs in a three second movement until the body reaches a straight line. The body is then lowered to the ground in a three second movement, the foot of the lower leg touches the ground before performing another repetition.
Study NCT02896400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Negotiated Interview (BNI)
Description: Brief motivational interview on smoking behavior
Study NCT02896400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Description: 6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
Study NCT02896400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT Smokers Quitline (QL)
Description: Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling.
Study NCT02896400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SmokefreeText (Text)
Description: Enrollment in a version of NCI's SmokefreeTxt, tailored for the study.
Study NCT02864641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planet K
Description: Planet K is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' chronic kidney disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
Study NCT05550129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Oral tablet
Study NCT05550129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral tablet
Study NCT01896895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobulinumtoxinA (Xeomin), 25 Units
Description: IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.
Study NCT01896895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin), 12.5 Units
Description: IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.
Study NCT01896895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study NCT01896895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin), 35 Units
Description: IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Open-Label Extension: up to 35 Units per eye.
Study NCT01896895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IncobotulinumtoxinA (Xeomin), 35 Units
Description: IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Open-Label Extension: up to 35 Units per eye.
Study NCT02472756 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: The choice of the chemotherapy regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
Study NCT02472756 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: The choice of the rituximab regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
Study NCT02248129 — intervention group
Intervention type: DRUG
Intervention: Telmisartan and hydrochlorothiazide
Study NCT04699994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT therapy
Description: Preoperative FLOT therapy
Study NCT01195467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada/Raltegravir
Description: All subjects currently on Atripla® will switch to Truvada/Raltegravir
Study NCT02837432 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydrocortisone acetate
Study NCT02837432 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study NCT01795924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-616
Description: Patients may continue treatment through 1 year post-C1D1 or until withdrawal of consent or development of any toxicity meeting the definition of Dose-Limiting Toxicity or progressive disease, whichever occurs first.
Study NCT03886064 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multi-behavioral intervention
Description: The interventional group will then meet regularly under the aegis of the trainer to work on modifying each person's risk factors. The one-hour sessions will be scheduled every two weeks for two months and then every month for two months and then every three months until the end of the study (13 sessions). These sessions will be behavior change sessions, focused on goal setting, action planning, and problem solving. Trainers will facilitate these sessions and use motivational interviewing techniques
Study NCT02488785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Diabetes Self-Care and Education Program
Description: Participants will be able to have frequent contact in order to share physical activity and glucose data with the diabetes educator using the smartphone they will receive. Information downloaded to the Glooko Population Management tool can be shared with the diabetes educator.
Study NCT02488785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Participants will be given a Fitbit physical activity tracker which they can use to record their activity and share the information with the diabetes educator using the device's smartphone application.
Study NCT02488785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Description: All virtual visits were performed via provided smartphone. In addition, participants will receive a Glooko MeterSync Blue cable which is able to connect to most glucose meters in order to download glucose data to the Glooko Population Management tool on their smartphones
Study NCT05676671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Applications of self-etching adhesives and dental restorations
Study NCT01730495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Weekly subcutaneous injections of Etanercept 50 mg, for up to 12 months.
Study NCT04512937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation surgery
Description: Computer navigation-assisted surgery has two main elements; the pre-procedural planning to create accurate 3D images of the pelvis allowing the surgical team to achieve an accurate perception of the operative field, and intraoperative navigation where these images are used for anatomical guidance to enhance surgical precision. Accordingly, computer software is used in this study to outline the tumour and other pelvic organs on pre-operative images which are subsequently used for intraoperative navigation.
Study NCT04440293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BBAT
Description: The BBAT was applied by a trained and certified physiotherapist in this area for about an hour, two days a week, as a group therapy. The BBAT program includes movements related to daily activities such as lying, sitting, standing and walking. BBAT focuses on basic movement principles such as postural stability, energy adjustment in movements, comfortable breathing and coordination.
Study NCT04440293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT
Description: The CT program was applied two days a week for about an hour. The CT program includes active range of motion (ROM) exercises, stretching, isometric and resistant strengthening, posture exercises and relaxation training.
Study NCT01075334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Porimore - A Carnitine based food supplement
Description: A daily dose of 2 grams L-carnitine, 1 gr acetyl L-carnitine, 500mg Vitamin C, 400 IU vitamin E, 60 mg Q10, 30mg Zinc Picolinate, 500mcg Folic Acid, 200 Mcg Selenium, 100 MCG Vitamin B12.
Study NCT00584831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: toric contact lens
Study NCT01075334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc and Folate Supplementation
Description: 500 Mcg Folic acid, 30-60 mg Zinc tablets/ day
Study NCT03427918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Sex Therapy
Description: Mindfulness-Based Sex Therapy in an integration of psychoeducation, sex therapy, and mindfulness-based skills.
Study NCT03226067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GKT137831
Description: GKT137831 100mg capsules. To be taken as part of two dose arms which are 400mg twice daily or 400mg once daily.
Study NCT03226067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Matching capsules.
Study NCT03226067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching capsules.
Study NCT00954213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIR/Floortime parent intervention
Description: Parent will be trained to observe their autistic child's cues, follow their child's lead and techniques to enhance his/her development.
Study NCT01845155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuro-Music-Therapy according to the Heidelberg Model
Description: The neuro-music therapy according to the Heidelberg Model for tinnitus is a manualized short term music therapeutic treatment lasting for nine consecutive 50-minutes sessions of individualized therapy. Therapy takes place on five consecutive days (from Monday to Friday) with two therapy sessions per day. It comprises both active and receptive forms of music therapy. The interventions are structured into the following modules Directive Counseling, Resonance Training, Neuroauditive Cortex Training, Tinnitus Reconditioning.~For more details on the music therapy see Argstatter et al. 2012
Study NCT01845155 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselling
Description: Duration: single session of 50 min Tinnitus specific procedures: The counseling group receives the identical counselling procedure as the music therapy group.
Study NCT04522297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine/Octreotide
Description: oral midodrine plus octreotide as subcutaneous injection
Study NCT04522297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nor-epinephrine
Description: Intravenous infusion norepinephrine
Study NCT00584831 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: toric contact lens
Study NCT02653196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy
Description: Allogeneic hematopoietic stem cell transplant (HSCT) following thiotepa-based marrow ablative chemotherapy (MAC) for children with high-grade and/or recurrent neuro-epithelial and other solid tumors.
Study NCT02653196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keratinocyte Growth Factor
Description: KGF 60 mcg/kg IV: 6 doses
Study NCT02653196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab 12 mg/m2 IV: 2 doses (not given if matched related donor is 10/10 HLA matched sibling donor)
Study NCT02653196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa 300 mg/m2 IV: 3 doses
Study NCT02653196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m2 IV: 3 doses
Study NCT02653196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 IV: 3 doses
Study NCT02653196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 70 mg/m2 IV: Day 2 doses
Study NCT02653196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus 0.05 mg/kg/day IV (Cyclosporine may be substituted for Tacrolimus): Start Day -2, begin taper on Day +100, discontinue on Day +180
Study NCT02653196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Cyclosporine A dosed as follows: Age ≤ 6 years: 6 mg/kg/day IV in divided doses (e.g. 2 mg/kg every 8 hours) OR Age > 6 years: 3 mg/kg/day IV in divided doses (1.5 mg/kg every 12 hours): Start Day -2, begin taper on Day +100, discontinue on Day +180
Study NCT02653196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 15 mg/kg every 8 hours oral or IV: Start Day 0 (4-6 hours post stem cell infusion) to Day +40, then taper weekly until discontinuation on Day +90
Study NCT01299233 — intervention group
Intervention type: DEVICE
Intervention: Spectralis® SD-OCT, Heidelberg Engineering GmbH, H
Description: Measurement of the peripapillar nerve fiber layer with different settings of ART
Study NCT03252821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: High-intensity interval training sessions will be conducted on cycle ergometers or treadmill with heart rate measured throughout each session.
Study NCT03252821 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: Resistance exercise will be performed on eight exercises targeting major muscle groups at 60% to 85% of their estimated one-repetition maximum (1RM).
Study NCT00306592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG00002 (natalizumab)
Study NCT01302964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo will receive placebo for duration of the study
Study NCT01302964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Subjects will receive 7.5 mg daily at the start of the trial. The dose will be increased by 7.5 mg per week for subjects weighing less than 50 kg and up to 15 mg per week for subjects weighing more than 50 kg depending on efficacy and tolerability.
Study NCT01347190 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR002 Liquid API
Description: A single nominal dose of CR002 (three different dose groups) will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
Study NCT01347190 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single nominal dose of Placebo will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
Study NCT02204254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequence
Description: Associated to arm radiofrequence
Study NCT02204254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxycycline
Description: doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
Study NCT03899610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy+Durvalumab+Tremelimumab
Description: 1. Neoadjuvant treatment:~   Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)~2. Interval debulking surgery~3. Adjuvant treatment:~Standard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)
Study NCT00989729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: A single preoperative dosage 30 mg/kg Methylprednisolone suspended in physiological saline (100 ml in total) given intravenously as a 30 minute infusion, 2 hours before surgery.
Study NCT00989729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological Saline
Description: A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery